Nigeria's HIV burden is significant and well-documented. According to Bayesian modelling using UNAIDS 2022 Spectrum data..

Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the use of lenacapavir expands, scientists are probing a critical question: If ...

This report developed by UNAIDS and the United for Global Mental Health reviews and maps Global Fund investments in priority HIV and TB comorbidities in Grant Cycle 7 (GC7), including key ...

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

Researchers here presented what they said is the first evidence demonstrating that benefits paid through the Supplemental Nutrition Assistance Program, or SNAP, can improve a person’s adherence to HIV ...

Executive actions in 2025 produced a 90-day freeze and stop orders; waivers incompletely restored services, with notable gaps in PrEP access for nonpregnant, nonbreastfeeding individuals. New research ...

Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.

Zimbabwe is now one of the first countries in the world to start a lenacapavir program, which was made possible through funding from the United States government and The Global Fund.

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.

The tiny shell protecting the HIV virus resembles a slightly rounded ice cream cone, but there is nothing sweet about it.